Guidelines for Therapy of Autoimmune Liver Disease

Hiromi Ishibashi; Atsumasa Komori; Shinji Shimoda; M. Eric Gershwin

doi:10.1055/s-2007-979472

Seminars in Liver Disease, Inhaltsverzeichnis

Semin Liver Dis 2007; 27(2): 214-226
DOI: 10.1055/s-2007-979472

Guidelines for Therapy of Autoimmune Liver Disease

Hiromi Ishibashi¹ , Atsumasa Komori¹ , Shinji Shimoda² , M. Eric Gershwin³

¹Clinical Research Center, National Hospital Organization (NHO), Nagasaki Medical Center, and Department of Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
²Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
³Division of Rheumatology, Allergy, and Clinical Immunology, University of California at Davis School of Medicine, Genome and Biomedical Sciences Facility, Davis, California

Abstract

ABSTRACT

The principle of therapy for chronic inflammatory liver diseases is the removal of causal agents. For autoimmune liver diseases, however, total removal of causal agents and immune cells is impossible. Therefore, autoimmune liver diseases are presently treated by suppression of the immune response. Autoimmune hepatitis is characteristically responsive to corticosteroids, often used in combination with azathioprine to obtain a steroid-sparing effect. For primary biliary cirrhosis, ursodeoxycholic acid is safe and is the first choice for treatment. Treatment of this autoimmune liver disease should also address various symptoms and complications arising from any associated autoimmune diseases, particularly cholestasis and cirrhosis-related complications. For primary sclerosing cholangitis there are no established immunomodulatory therapies, but medical, endoscopic, and surgical treatments are applicable to this disease. Liver transplantation becomes indicated during the eventual end stages of each of these immune-mediated liver diseases.

KEYWORDS

Treatment - guideline - autoimmune hepatitis - primary biliary cirrhosis - primary sclerosing cholangitis - overlapping syndrome

Volltext

Referenzen

REFERENCES

1 Krawitt E L. Autoimmune hepatitis. N Engl J Med. 2006; 354 54-66
2 Krawitt E L, Bonis P AL. Treatment of autoimmune hepatitis. http://Available at: www.uptodate.com Accessed October 2006
3 Roberts S K, Therneau T M, Czaja A J. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology. 1996; 110 848-857
4 Czaja A J, Freese D K. Diagnosis and treatment of autoimmune hepatitis. Hepatology. 2002; 36 479-497
5 Mackay I R. Chronic hepatitis: effect of prolonged suppressive treatment and comparison of azathioprine with prednisolone. Q J Med. 1968; 37 379-392
6 Murray-Lyon I M, Stern R B, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet. 1973; 1 735-737
7 Summerskill W H, Korman M G, Ammon H V, Baggenstoss A H. Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut. 1975; 16 876-883
8 Manns M P, Vogel A. Autoimmune hepatitis, from mechanisms to therapy. Hepatology. 2006; 43(suppl 1) S132-S144
9 Czaja A J, Wolf A M, Baggenstoss A H. Laboratory assessment of severe chronic active liver disease (CALD): correlation of serum transaminase and gamma globulin levels with histologic features. Gastroenterology. 1981; 80 687-692
10 Nakamura K, Yoneda M, Yokohama S et al.. Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis. J Gastroenterol Hepatol. 1998; 13 490-495
11 Kanzler S, Gerken G, Lohr H et al.. Duration of immunosuppressive therapy in autoimmune hepatitis. J Hepatol. 2001; 34 354-355
12 Czaja A J, Ludwig J, Baggenstoss A H, Wolf A. Corticosteroid-treated chronic active hepatitis in remission: uncertain prognosis of chronic persistent hepatitis. N Engl J Med. 1981; 304 5-9
13 Czaja A J, Davis G L, Ludwig J, Taswell H F. Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis. Hepatology. 1984; 4 622-627
14 Czaja A J. Low-dose corticosteroid therapy after multiple relapses of severe HBsAg-negative chronic active hepatitis. Hepatology. 1990; 11 1044-1049
15 Johnson P J, McFarlane I G, Williams R. Azathioprine for long term maintenance of remission in autoimmune hepatitis. N Engl J Med. 1995; 333 958-963
16 Czaja A J. Understanding the pathogenesis of autoimmune hepatitis. Am J Gastroenterol. 2001; 96 1224-1231
17 Czaja A J, Menon K V, Carpenter H A. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Hepatology. 2002; 35 890-897
18 Schalm S W, Ammon H V, Summerskill W H. Failure of customary treatment in chronic active liver disease: causes and management. Ann Clin Res. 1976; 8 221-227
19 Pratt D S, Flavin D P, Kaplan M M. The successful treatment of autoimmune hepatitis with 6-mercaptopurine after failure with azathioprine. Gastroenterology. 1996; 110 271-274
20 Fernandes N F, Redeker A G, Vierling J M et al.. Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis. Am J Gastroenterol. 1999; 94 241-248
21 Aqel B A, Machicao V, Rosser B et al.. Efficacy of tacrolimus in the treatment of steroid refactory autoimmune hepatitis. J Clin Galtroenteros. 2004; 38 805-809
22 Burak K W, Urbanski S J, Swain M G. Successful treatment of refractory type 1 autoimmune hepatitis with methotrexate. J Hepatol. 1998; 29 990-993
23 Richardson P D, James P D, Ryder S D. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J Hepatol. 2000; 33 371-375
24 Feld J J, Dinh H, Arenovich T et al.. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology. 2005; 42 53-62
25 Miyake T, Miyaoka H, Abe M et al.. Clinical characteristics of autoimmune hepatitis in older aged patients. Hepatol Res. 2006; 36 139-142
26 Cook G C, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med. 1971; 40 159-185
27 Roberts S K, Therneau T, Czaja A J. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology. 1996; 110 848-857
28 Dufour J F, De Lellis R, Kaplan M M. Reversibility of hepatic fibrosis in autoimmune hepatitis. Ann Intern Med. 1997; 127 981-985
29 Malekzadeh R, Mohamadnejad M, Nasseri-Moghaddam S et al.. Reversibility of cirrhosis in autoimmune hepatitis. Am J Med. 2004; 117 125-129
30 Sanchez-Urdazpal L, Czaja A J, van Hoek B et al.. Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. Hepatology. 1992; 15 215-221
31 Ratziu V, Samuel D, Sebagh M et al.. Long-term follow-up after liver transplantation for autoimmune hepatitis: evidence of recurrence of primary disease. J Hepatol. 1999; 30 131-141
32 Gonzalez-Koch A, Czaja A J, Carpenter H A et al.. Recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver Transpl. 2001; 7 302-310
33 Czaja A J, Davis G L, Ludwig J, Taswell H F. Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis. Hepatology. 1984; 4 622-627
34 Ferrero S, Ragni N. Inflammatory bowel disease: management issues during pregnancy. Arch Gynecol Obstet. 2004; 270 79-85
35 Park S Z, Nagorney D M, Czaja A J. Hepatocellular carcinoma in autoimmune hepatitis. Dig Dis Sci. 2000; 45 1944-1948
36 Maggiore G, Veber F, Bernard O et al.. Autoimmune hepatitis associated with anti-actin antibodies in children and adolescents. J Pediatr Gastroenterol Nutr. 1993; 17 376-381
37 Gregorio G V, Portmann B, Reid F et al.. Autoimmune hepatitis in childhood: a 20 year survey. Hepatology. 1997; 25 541-547
38 Mieli-Vergani G, Vergani D. Autoimmune hepatitis in children. Clin Liver Dis. 2002; 6 623-634
39 Alvarez F, Ciocca M, Canero-Velasco C et al.. Short-term cyclosporine induces a remission of autoimmune hepatitis in children. J Hepatol. 1999; 30 222-227
40 Steven M M, Buckley J D, Mackay I R. Pregnancy in chronic active hepatitis. Q J Med. 1979; 48 519-531
41 Heneghan M A, Norris S M, O'Grady J G et al.. Management and outcome of pregnancy in autoimmune hepatitis. Gut. 2001; 48 97-102
42 Schramm C, Herkel J, Beuers U et al.. Pregnancy in autoimmune hepatitis: outcome and risk factors. Am J Gastroenterol. 2006; 101 556-560
43 Bellary S, Schiano T, Hartman G et al.. Chronic hepatitis with combined features of autoimmune chronic hepatitis and chronic hepatitis C: favorable response to prednisone and azathioprine. Ann Intern Med. 1995; 123 32-34
44 Nakamura K, Yoneda M, Takamoto S et al.. Effect of ursodeoxycholic acid on autoimmune-associated chronic hepatitis C. J Gastroenterol Hepatol. 1999; 14 413-418
45 Kaplan M M, Gershwin M E. Primary biliary cirrhosis. N Engl J Med. 2005; 353 1261-1273
46 Kaplan M M. Overview of the treatment of primary biliary cirrhosis. http://Available at: www.uptodate.com Accessed October 2006
47 Gershwin M E, Mackay I R. Primary biliary cirrhosis: paradigm or paradox for autoimmunity. Gastroenterology. 1991; 100 822-833
48 Aoki C A, Roifman C M, Lian Z X et al.. IL-2 receptor alpha deficiency and features of primary biliary cirrhosis. J Autoimmun. 2006; 27 50-53
49 Selmi C, Invernizzi P, Keeffe E B et al.. Epidemiology and pathogenesis of primary biliary cirrhosis. J Clin Gastroenterol. 2004; 38 264-271
50 Rieger R, Leung P S, Jeddeloh M R et al.. Identification of 2-nonynoic acid, a cosmetic component, as a potential trigger of primary biliary cirrhosis. J Autoimmun. 2006; 27 7-16
51 Heathcote E J. AASLD guideline: management of primary biliary cirrhosis. Hepatology. 2000; 31 1005-1013
52 Poupon R E, Poupon R, Balkau B. The UDCA-PBC Study Group . Ursodiol for the long-term treatment of primary biliary cirrhosis. N Engl J Med. 1994; 330 1342-1347
53 Lindor K D, Dickson E R, Baldus W P et al.. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology. 1994; 106 1284-1290
54 Combes B, Carithers R L, Maddrey W C et al.. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology. 1995; 22 759-766
55 Poupon R E, Lindor K D, Cauch-Dudek K, Dickson E R, Poupon R, Heathcote E J. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology. 1997; 113 884-890
56 Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology. 2006; 130 715-720
57 Nakai S, Masaki T, Kurokohchi K et al.. Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: a preliminary study. Am J Gastroenterol. 2000; 95 326-327
58 Kurihara T, Maeda A, Shigemoto M et al.. Investigation into the efficacy of bezafibrate against primary biliary cirrhosis, with histological references from cases receiving long term monotherapy. Am J Gastroenterol. 2002; 97 212-214
59 Yano K, Kato H, Morita S et al.. Is bezafibrate histologically effective for primary biliary cirrhosis'. Am J Gastroenterol. 2002; 97 1075-1077
60 Dohmen K, Mizuta T, Nakamuta M, Shimohashi N, Ishibashi H, Yamamoto K. Fenofibrate for patients with asymptomatic primary biliary cirrhosis. World J Gastroenterol. 2004; 10 894-898
61 Sakauchi F, Mori M, Zeniya M, Toda G. A cross-sectional study of primary biliary cirrhosis in Japan: utilization of clinical data when patients applied to receive public financial aid. J Epidemiol. 2005; 15 24-28
62 Elta G H, Sepersky R A, Goldberg M J et al.. Increased incidence of hypothyroidism in primary biliary cirrhosis. Dig Dis Sci. 1983; 28 971-975
63 Shibuya A, Tanaka K, Miyakawa H et al.. Hepatocellular carcinoma and survival in patients with primary biliary cirrhosis. Hepatology. 2002; 35 1172-1178
64 Jones D EJ, Metcalf J V, Collier J D, Bassendine M F, James O FW. Hepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes. Hepatology. 1997; 26 1138-1142
65 Nijhawan P K, Therneau T M, Dickson E R, Boynton J, Lindor K D. Incidence of cancer in primary biliary cirrhosis: the Mayo experience. Hepatology. 1999; 29 1396-1398
66 Markus B H, Dickson E, Grambsch P et al.. Efficiency of liver transplantation in patients with primary biliary cirrhosis. N Engl J Med. 1989; 320 1709-1713
67 Polson R J, Portmann B, Neuberger J, Calne R Y, Williams R. Evidence for disease recurrence after liver transplantation for primary biliary cirrhosis: clinical and histologic follow-up studies. Gastroenterology. 1989; 97 715-725
68 Balan V, Batts K P, Porayko M K, Krom R AF, Ludwig J, Wiesner R H. Histological evidence for recurrence of primary biliary cirrhosis after liver transplantation. Hepatology. 1993; 18 1392-1398
69 Dickson E R, Grambsch P M, Fleming T R, Fisher L D, Langworthy A. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology. 1989; 10 1-7
70 Kim W R, Wiesner R H, Therneau T M et al.. Optimal timing of liver transplantation for primary biliary cirrhosis. Hepatology. 1998; 28 33-38
71 Nakamura M, Shimizu-Yoshida Y, Takii Y et al.. Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis. J Hepatol. 2005; 42 386-392
72 Nakamura M, Kondo H, Mori T et al.. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology. 2007; 45 118-127
73 Czaja A J. Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology. 1998; 28 360-365
74 Boberg K M, Fausa O, Haaland T et al.. Features of autoimmune hepatitis in primary sclerosing cholangitis: an evaluation of 114 primary sclerosing cholangitis patients according to a scoring system for the diagnosis of autoimmune hepatitis. Hepatology. 1996; 23 1369-1376
75 Poupon R, Chazouilleres O, Corpechot C, Chretien Y. Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis. Hepatology. 2006; 44 85-90
76 Czaja A J. The variant forms of autoimmune hepatitis. Ann Intern Med. 1996; 125 588-598
77 Ben-Ari Z, Dhillon A P, Sherlock S. Autoimmune cholangiopathy: part of the spectrum of autoimmune chronic active hepatitis. Hepatology. 1993; 18 10-15
78 Colombato L A, Alvarez F, Cote J et al.. Autoimmune cholangiopathy: the result of consecutive primary biliary cirrhosis and autoimmune hepatitis. Gastroenterology. 1994; 107 1839-1843
79 Goodman Z D, McNally P R, Davis D R et al.. Autoimmune cholangitis-a variant of primary biliary cirrhosis: clinicopathologic and serologic correlations in 200 cases. Dig Dis Sci. 1995; 40 1232-1242
80 Chazouillères O, Wendum D, Serfaty L et al.. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology. 1998; 28 296-301
81 Joshi S, Cauch-Dudek K, Wanless I R et al.. Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid. Hepatology. 2002; 35 409-413
82 LaRusso N F, Shneider B L, Black D et al.. Primary sclerosing cholangitis: summary of a workshop. Hepatology. 2006; 44 746-764
83 Wiesner R H, Porayko M K, Hay J E et al.. ER liver transplantation for primary sclerosing cholangitis: impact of risk factors on outcome. Liver Transpl Surg. 1996; 2(suppl 1) 99-108
84 Floreani A, Rizzotto E R, Ferrara F et al.. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. Am J Gastroenterol. 2005; 100 1516-1522

1 Comments on the AASLD guideline[4]: for precise explanation refer to the original article (ref. 4).

1 I, evidence from multiple well-designed randomized controlled trials, each involving a number of participants to be of sufficient statistical power.

1 II, evidence from at least one large, well-designed clinical trial with or without randomization, from cohort or case-control analytic studies, or from well-designed meta-analysis.

1 III, evidence based on clinical experience, descriptive studies, or reports of expert committees.

1 IV, not rated.

2 Comments on the AASLD guideline[51]:

2 Categories reflecting the evidence to support the use of a guideline recommendation (category and definition):

2 A, Survival benefit; B, improved diagnosis; C, improvement in quality of life; D, relevant pathophysiologic parameters improved; E, impacts, cost of health care.

2 These standardized guidelines of the practice guideline of the AASLD have been modified from the categories of the Infectious Diseases Society of America's quality standards (cited from ref. 50). For precise explanation, refer to the original article (ref. 51).

Hiromi IshibashiM.D.

Director General, Clinical Research Center, National Hospital Organization (NHO), Nagasaki Medical Center

Kubara 2-1001-1, Omura, Nagasaki, 856-8562, Japan